KOSDAQBiotech & Pharma387690

Remedi

₩18,890▼ 1.67%2026-10-02 close

Market Cap

₩144.7B

Turnover

₩9.9B

Volume

520,000 shares

Shares out.

7.6M

PER

—

PBR

7.7×

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Profitable Tech-Exception IPO: Procurement Dependency in Focus

REMEDI, which entered KOSDAQ via the technology exception track in July 2026, stands out as a rare profitable medical device IPO underpinned by Indian public healthcare procurement, yet its concentration in a single product and procurement-dependent revenue model remains the defining variable for earnings sustainability.

1
Operating profit turned positive in 2024; KRW 2.8 billion in 2025 (+191% YoY) and KRW 3.3 billion in Q1 2026 alone, reflecting rapid margin expansion
2
India's NTEP and CMSS procurement contracts are the primary growth driver; on listing day REMEDI exclusively passed technical qualification for India's Odisha state government tender, raising expectations of additional contracts
3
The flagship KA6 portable X-ray device accounts for 92.7% of Q1 2026 revenue, indicating high single-product concentration risk
4
Selected by NASA from 200+ competing products globally and notified of inclusion in a SpaceX research program; pursuing diversification across three pillars: medical, NDT, and aerospace
5
Immediately tradeable float of 41.03% rising to 54% within three months post-IPO constitutes a notable near-term supply overhang

Business structure

REMEDI, founded in July 2012 and certified as an INNOBIZ and venture enterprise, has built its technology moat by in-house developing key components including X-ray tubes, emitters, and high-voltage power supplies, establishing expertise in low-dose, miniaturized X-ray solutions.

The core business is medical portable X-ray imaging, with the medical segment accounting for 92.7% of total Q1 2026 revenue, centered on the KA6 product line and the XCAM digital X-ray system series.

The company targets the structural shift in demand from large fixed-installation X-ray systems toward portable and mobile devices, focusing primarily on public healthcare procurement in emerging markets where healthcare accessibility is limited.

In the industrial segment, REMEDI develops NDT equipment for battery, semiconductor, and food manufacturing inspection processes; its battery inspection system, the RIX B100, is currently undergoing technical validation on the production lines of a global North American manufacturer.

Aerospace is an emerging growth pillar: NASA selected REMEDI's portable X-ray device from among more than 200 competing products globally in 2024 and assessed its performance in space environments for approximately 18 months, followed by a notification in 2026 that the product had been designated as a research technology participant for the SpaceX program.

REMEDI has passed technology assessments three consecutive times—A·BBB in 2022, A·A in 2024, and A·BBB in 2025—and this marks its third IPO attempt after withdrawals in 2022 and 2024.

Unlike tech-exception peers such as Nextbiomed and Graphy, which were reporting operating losses at their respective IPO dates, REMEDI listed with two consecutive years of operating profitability—a key differentiating point in its IPO narrative.

The global portable X-ray devices market is estimated at approximately USD 9.17 billion in 2025 with projected annual growth of around 9% (Mordor Intelligence), but the same emerging-market procurement channels are contested by global majors including GE HealthCare, Fujifilm, and Canon Medical, as well as price-competitive Chinese manufacturers.

Recent trends

Based on DART consolidated financial disclosures, REMEDI's revenue surged from KRW 6.9 billion in 2023 to KRW 13.4 billion in 2024 (+94.3%) and continued growing to KRW 14.6 billion in 2025 (+8.8%).

Operating profit reversed from a loss of KRW 2.3 billion in 2023 to a gain of KRW 0.9 billion in 2024 and further expanded to KRW 2.8 billion in 2025 (exceeding +191% YoY); net profit surged to KRW 5.1 billion, up 586% YoY in 2025.

Operating margin improved from approximately 6.7% in 2024 to 19.1% in 2025, with further expansion to approximately 35% in Q1 2026.

Q1 2026 consolidated results—revenue KRW 9.4 billion (+142.5% YoY, representing 64% of full-year 2025 revenue in a single quarter), operating profit KRW 3.3 billion, net profit KRW 3.0 billion—surpassed the company's full-year 2025 operating profit in a single quarter.

This profitability surge was driven by expanded shipments to India's Central Medical Services Society (CMSS) and overseas sales diversification; deliveries to India's NTEP totaled approximately 1,534 units in 2025 with an additional 750 units shipped in July 2026.

The company listed on KOSDAQ on July 13, 2026, with institutional demand of 1,146-to-1 and retail subscription orders of approximately KRW 5.3 trillion, pricing the IPO at the top of the band at KRW 20,700 per share.

Shares surged 38.65% intraday on listing day to KRW 28,700 before retracing to close near the IPO price; on July 14 (day two of trading), the stock was priced at KRW 22,000 (+6.28% from the previous session, market capitalization approximately KRW 200 billion).

On listing day, REMEDI also received news that it had exclusively passed technical qualification in India's Odisha state government tender for portable digital X-ray equipment after defeating global competitors in a multi-stage technical assessment, with final contract size to be determined after the remaining price bidding process.

Lead underwriter KB Securities derived a per-share fair value of KRW 32,639 using a PER of 21.95x on comparable peers (Viewworks, IRAY GROUP, Detection Technology Oyj), then applied a discount of up to 45.5% to arrive at the offering range—placing REMEDI second-highest by IPO price band ceiling among KOSDAQ technology-exception medical device listings over the past five years.

Outlook

The company is pursuing a restructuring around three business pillars—medical, NDT, and aerospace—deploying approximately KRW 24.2 billion in net IPO proceeds across facility investment (KRW 7.1 billion for production automation and overseas manufacturing bases), operating funds (KRW 12.1 billion for R&D, next-generation products, and global marketing), and debt repayment (KRW 5.0 billion).

Upon completion of its second-phase production automation by 2028, annual X-ray device manufacturing capacity is targeted to reach up to 7,700 units, which could meaningfully expand the company's ability to fulfill large-scale global procurement orders.

The exclusive technical qualification in the Odisha state government tender has been cited as a reference position for engaging India's 27 remaining state governments and additional central government programs, though final contract sizes will be confirmed only after the price bidding process and associated administrative procedures are completed.

The inherently lumpy nature of public procurement revenue—subject to national budget cycles, policy shifts, and tender scheduling—means that converting individual contract wins into stable recurring purchase orders remains the defining operational challenge for medium-to-long-term earnings stability.

The company articulates a platform strategy including AI-driven medical imaging software, next-generation X-ray product development, and broader regulatory approvals, though revenue contributions from these areas remain limited as of current reporting.

Market commentary broadly observes that achieving the approximately KRW 19.9 billion projected 2028 net income underlying the IPO valuation will depend on the continuity of India shipments, geographic revenue diversification, and the pace of commercial progress in the NDT and aerospace segments.

Bull factors

Exceptional Profitability Among Tech-Exception Medical Device IPOs

REMEDI listed on KOSDAQ with two consecutive years of operating profitability—an unusual characteristic among medical device companies pursuing the technology exception track.

Its 2025 operating margin of approximately 19% contrasted markedly with IPO-stage peers such as Nextbiomed and Graphy, which were reporting operating losses at their respective listing dates; this figure further expanded to approximately 35% in Q1 2026.

High-value product mix and fixed-cost leverage from large-batch public procurement contracts are identified as the primary drivers of margin improvement.

If the profitability trajectory is sustained, the company may serve as a benchmark case for earnings-based credibility within the tech-exception medical device segment.

Deepening Reference Base in India's Public Healthcare Procurement

REMEDI became the first foreign company to win a large-scale NTEP tender in India, delivering approximately 1,534 units in 2025 and an additional 750 units in July 2026, and has also secured supply records with India's Employee State Insurance Corporation, Thailand's Public Health Department, and Indonesia's Ministry of Health.

On KOSDAQ listing day in July 2026, the company exclusively passed technical qualification for the Odisha state government's portable digital X-ray tender after defeating global competitors in a multi-stage assessment—an outcome assessed as creating a reference position for engaging the remaining 27 Indian state government procurement programs.

The WHO's classification of mobile radiography as essential medical equipment and the ongoing global TB elimination programs provide a structural tailwind that continues to broaden public procurement demand in emerging markets.

The accumulating procurement track record in India could serve as the foundation for broader expansion across Southeast and South Asia.

Multi-Vertical Expansion Potential: Medical, NDT, and Aerospace

Built on its proprietary X-ray technology platform, REMEDI is advancing beyond medical devices into NDT equipment for battery and semiconductor inspection as well as the aerospace sector.

NASA's selection of REMEDI's device from over 200 competing products globally and the subsequent SpaceX research technology designation serve as third-party validations of the company's technical credibility.

The battery inspection system (RIX B100) is currently undergoing technical validation on the production lines of a North American global manufacturer; successful commercialization could open access to the high-growth electric vehicle and semiconductor industries.

Transitioning into AI-based medical imaging software and platform solutions is articulated as a medium-to-long-term diversification strategy that, if realized, could broaden the company's addressable market.

Bear factors

Single-Product and Public Procurement Concentration

Medical segment revenue centered on the KA6 product line accounted for 92.7% of Q1 2026 total sales, a concentration that has increased every year from 67.2% in 2023, to 86.4% in 2024, to 87.3% in 2025.

A substantial portion of this medical revenue is tied to Indian public procurement, leaving the company's financials highly exposed to KA6 demand slowdowns, competitive pressure, or Indian government policy changes.

In developed-market channels, global incumbents such as GE HealthCare, Fujifilm, and Canon Medical carry structural advantages in brand recognition, after-sales service networks, and distribution depth.

A delay in portfolio diversification or in generating meaningful revenue from the NDT and aerospace segments could amplify the structural vulnerability of the current earnings base.

Public Procurement Volatility and Rising Receivables

The public procurement-centric business model is inherently subject to variability in contract volume and revenue recognition timing, as both depend on each government's budget cycle, policy priorities, and tender schedules.

According to reporting by DealSite Economics TV, accounts receivable have grown sharply alongside revenue expansion and receivable turnover has declined, increasing working capital pressure even as the profitability trend continues.

The approximately KRW 19.9 billion projected 2028 net income underpinning the IPO valuation has been criticized for depending heavily on as-yet-unproven follow-on products and package sales expansions.

Delays in order delivery or payment collection could place meaningful pressure on cash flows, warranting quarterly monitoring.

Post-IPO Overhang and Governance Concerns

Per Financial Supervisory Service disclosures, the immediately tradeable float stands at 41.03% (3,129,160 shares) of post-IPO total shares outstanding, expanding to 42.88% one month and 54% three months after listing.

Early-stage venture capital investors whose fund maturities have arrived may generate systematic selling pressure regardless of market conditions, and the KRW 762 billion in trading volume on the first post-IPO session—approximately 380% of market capitalization—signals substantial near-term supply-and-demand volatility.

Additionally, according to Simply Wall Street's analysis, the recent departure of a director has left the board without any independent directors, raising governance concerns regarding minority shareholder protection and decision-making transparency.

Lock-up expiration events over subsequent months are expected to create further incremental supply pressure as mandatory holding periods expire.

Risk factors

Emerging Market Policy and Currency Risk

A further strengthening of India's 'Make in India' policy toward mandating local manufacturing for foreign medical device suppliers could apply pressure to the current export-based delivery model over the medium to long term.

Public health budget variability or procurement policy changes in key markets including India, Indonesia, and the Philippines may affect contract volumes and recognition timing—a risk common to small-cap emerging-market exporters.

Currency volatility between the Korean won and the US dollar or local currencies also carries implications for reported revenue and operating margins.

REMEDI's planned establishment of overseas production bases in India, Indonesia, and the Philippines could provide a structural buffer against this policy risk, contingent on successful execution.

Earnings Estimate Miss Risk

The approximately KRW 19.9 billion projected 2028 net income used to underpin the IPO valuation relies heavily on revenue from as-yet-unproven follow-on products and package expansions, introducing meaningful uncertainty around its achievement.

The strong Q1 2026 results may reflect a temporal concentration of India CMSS deliveries; replicating that performance level in subsequent quarters may prove challenging, potentially creating a gap relative to market expectations over time.

Commercialization delays in the NDT and aerospace segments represent a downside variable for the earnings trajectory, and the current absence of a robust sell-side analyst coverage base elevates information asymmetry risk.

Post-listing quarterly order levels and margin trends will serve as critical indicators for assessing estimate achievability.

Competitive Intensification and Technology Substitution

The global portable X-ray devices market, estimated at approximately USD 9.17 billion in 2025 and projected to grow at a CAGR of around 9% (Mordor Intelligence), is contested by global majors including GE HealthCare, Fujifilm, and Canon Medical, as well as competitively priced Chinese manufacturers increasingly active in emerging-market public procurement channels.

The AI-based medical imaging software space is attracting a growing number of new entrants, making success in REMEDI's software-and-services transition strategy far from assured.

The technological advantages the company has established in low-dose miniaturized X-ray could be eroded by similar product launches from larger incumbents or aggressive pricing from Asian competitors.

Given the technology-intensive nature of the business, sustaining the current competitive position over the long term would likely require ongoing commitment to R&D investment.

Overall view

REMEDI distinguishes itself among tech-exception medical device listings by entering KOSDAQ with two consecutive years of operating profitability, and the deepening procurement references in India, the Q1 2026 earnings beat, and the exclusive technical qualification in the Odisha state tender collectively explain the strong market reception at IPO.

Concurrently, the concentration of over 90% of revenue in a single product dependent on Indian public procurement, the challenge of converting one-time large deliveries into recurring contracts, a tradeable float expanding from 41% to 54% within three months post-IPO, and the absence of independent directors on the board constitute structural variables that warrant careful and ongoing monitoring.

Market commentary broadly observes that achieving the approximately KRW 19.9 billion projected 2028 net income underlying the valuation will require meaningful, verified revenue contributions from NDT and aerospace ventures and measurable geographic diversification—outcomes yet to be demonstrated.

Key near-term indicators to watch include the final contract outcome of the Odisha state tender, quarterly order levels, operating margins, accounts receivable trends, and the pace of commercialization progress in the NDT and aerospace segments.

This report is provided for informational purposes only and does not constitute a recommendation to buy, sell, or hold any securities.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 12 more articles and sources

Report written 2026-07-14 · Data as of 2026-07-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.